The invention discloses a recombinant RSV (Respiratory Syncytial Virus) antigenome plasmid rRSV-EGFP. The sequence of the recombinant RSV antigenome plasmid rRSV-EGFP is shown as SEQ ID No.1. The invention also discloses a recombinant RSV obtained by rescuing the plasmid and application of the recombinant RSV in screening of an RSV resisting drug. A high-throughput screening method for screening the RSV resisting drug comprises the following steps: inoculating a host cell, and adding the recombinant RSV and to-be-screened drugs; detecting the fluorescence intensity of GFP (Green Fluorescence Protein); evaluating an RSV resisting effect of the to-be-screened drugs. According to the recombinant RSV antigenome plasmid rRSV-EGFP disclosed by the invention, interaction of the recombinant RSV for expressing the GFP and the host cell and to-be-screened compounds is utilized; as the expression level of the GFP is closely related to the replication level of a virus, the antivirus effect of the compound can be analyzed by detecting the fluorescence intensity, further a high-throughput drug screening model for the RSV is established, a large-scale drug screening is realized, and a foundation is laid for research and development of the RSV-resisting drug.